Could less chemo after transplant mean better survival?
NCT ID NCT07193420
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 32 times
Summary
This study tests whether a lower dose of a chemotherapy drug (cyclophosphamide) given after a half-matched stem cell transplant can help people with blood cancers live longer without severe complications. About 180 adults will be randomly assigned to receive either the standard dose or a reduced dose. The goal is to see if the lower dose reduces side effects while still preventing graft-versus-host disease and cancer relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Saint Antoine Hospital - Hematology Department
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.